AstraZeneca PLC Revenue & Financials

AstraZeneca reported Total Revenue of $58.739 billion for fiscal year 2025, an increase of 9% at actual exchange rates and 8% at constant exchange rates over the $54.073 billion recorded in 2024. This growth trajectory represents a compound annual growth rate of approximately 15% since 2020, when revenue stood at $26.6 billion, confirming AstraZeneca as the fastest-growing major pharmaceutical company in the world over this period. Reported operating profit for 2025 reached $13.743 billion, up from $10.003 billion in 2024, yielding a reported operating margin of 23.4%. Core operating profit, which excludes intangible asset amortization, impairment, and other non-core items, increased to $18.4 billion in 2025 from $16.928 billion in 2024, representing a core operating margin of 31.3%. Net income for 2025 was $10.233 billion, up from $7.4 billion in 2024, with reported earnings per share of $6.60 and core earnings per share of $9.16, an 11% increase at constant exchange rates. The company's cash generation remains robust, with net cash inflow from operating activities of $11.861 billion in 2024 and approximately $13 billion in 2025, supporting capital expenditure of $3.27 billion in 2025, up 50% from $2.218 billion in 2024, as the company builds new manufacturing capacity in Virginia, Rockville, and China. AstraZeneca's balance sheet carries significant acquisition-related debt from the $39 billion Alexion transaction, but the company has maintained its investment-grade credit rating and reduced net debt through strong operating cash flows. The dividend policy remains progressive, with the board declaring a total dividend of $3.20 per share for 2025, up 3% from 2024. Looking ahead, AstraZeneca has issued guidance for 2026 expecting mid-to-high single-digit percentage growth in Total Revenue and low double-digit percentage growth in Core EPS, with a core tax rate between 18% and 22%. The company's financial architecture is characterized by industry-leading revenue growth, expanding margins as scale efficiencies compound, strong cash conversion, and disciplined capital allocation that prioritizes pipeline investment, debt reduction, and shareholder returns in equal measure. The gross profit margin on Product Sales was 84% in 2025, reflecting higher manufacturing costs and product mix shifts, with the company targeting margin improvement through scale efficiencies and biologics mix expansion. R&D expenditure reached $14.2 billion in 2025, representing 24% of Total Revenue, one of the highest ratios among major pharmaceutical companies. Selling, general, and administrative expenses were $18.9 billion, reflecting the global commercial infrastructure required to support 16 blockbuster medicines. The company's effective tax rate in 2025 was 20.5%, within the guided range, and the progressive dividend policy has delivered 23 consecutive years of dividend payments since the 1999 merger. The company has also maintained a strong balance sheet with net debt declining as operating cash flows exceed capital expenditure and dividend obligations. The financial narrative is therefore one of a company that has successfully converted scientific innovation into commercial revenue, commercial revenue into operating cash flow, and operating cash flow into sustained shareholder returns while maintaining the R&D investment necessary for future growth.